Extracorporeal photopheresis (ECP) is a cell-based immunotherapy that involves the
reinfusion of autologous leukocytes after exposure to psoralen and UVA. The treatment has …

Extracorporeal phototherapy (ECP) is a therapeutic approach based on the biological effect
of psoralen 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) on mononuclear cells …

Extracorporeal photopheresis (ECP) has had a major impact in the treatment of various
conditions in the past 25 years. Although it was initially developed for the treatment of …

Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy
majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory …

Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

The clinical use of extracorporeal photopheresis (ECP) for accepted indications such as
graft-versus-host disease, transplant rejection, and cutaneous T-cell lymphoma continues to …

Extracorporeal photopheresis (ECP) is an autologous cell therapy that is widely used for the
treatment of T cell-mediated diseases. ECP has been FDA-approved for the treatment of …

Extracorporeal photopheresis (ECP) is a combination of leukapheresis and photodynamic
therapy in which blood is treated with photoactivable drugs which are then activated with …

Extracorporeal photopheresis (ECP) is a technique that was developed> 20 years ago to
treat erythrodermic cutaneous T‐cell lymphoma (CTCL). The technique involves removal of …